Neuromyelitis Optica Spectrum Disorder Market Research
What is Neuromyelitis Optica Spectrum Disorder (NMOSD)?
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder of the central nervous system. The disease causes inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). NMOSD consists of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks), but symptoms often improve after the first attack. In its early stages, NMOSD may be confused with multiple sclerosis (MS). The cause of NMOSD is still unknown and symptoms include blurry vision, paralysis in legs or arms, nausea, vomiting, and painful spasms.
Spherix Global Insights – Neurology – Neuromyelitis Optica Spectrum Disorder (NMOSD)
Spherix’s Neurology team covers the NMOSD market in our Launch Dynamix™ service. Spherix’s has the following studies publishing this year covering NMOSD:
- Launch Dynamix™: Ultomiris (Alexion) in NMOSD (US)*
*Pending approval and launch
Spherix’s Launch Dynamix™ for NMOSD consists of quarterly deep dives during the first eighteen months of commercial availability probing launch KPIs, promotional activity, drivers and barriers to uptake, and patient types gravitating to the launch brand.
Follow Spherix Neurology on Social Media
Follow us for neurology industry news, insights & analysis:
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: